Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tivantinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 1/20 | 1.00 |
| ▸ | OPA1 | O60313 | 1/20 | 1.00 |
| ▸ | EIF5B | O60841 | 1/20 | 1.00 |
| ▸ | HMOX2 | P30519 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.37 |
| ▸ | CCND1 | P24385 | 2/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tivantinib SCHEMBL2036414 | 1.00 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL45306 | 1.00 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL12043258 | 1.00 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL29355700 | 1.00 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL44902 | 1.00 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL1395795 | 1.00 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL14865187 | 1.00 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL44944 | 1.00 | OPA1 (1.00) | OPA1EIF5BMETHMOX2HTR2A | |
| Tivantinib SCHEMBL2015821 | 0.96 | OPA1 (0.92) | OPA1EIF5BMETHMOX2HTR2A | |
| SCHEMBL12808552 | 0.94 | OPA1 (0.88) | OPA1EIF5BMETHMOX2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754078-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2013-06-13 | — | — | US | claimed |
| EP-2289892-B1 | Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer | ARQULE INC (US) | 2012-08-22 | — | — | EP | claimed |
| EP-1846406-B9 | MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2012-01-11 | — | — | EP | claimed |
| EP-2289892-A1 | Maleimide derivatives, pharmaceutical compositions amd methods for treatment of cancer | ArQule, Inc. (US) | 2011-03-02 | — | — | EP | claimed |
| EP-1846406-B1 | MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2010-11-03 | — | — | EP | claimed |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-09-02 | — | — | US | claimed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | claimed |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. | 2006-10-05 | — | — | US | claimed |
| US-20220184090-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | NOVARTIS AG (CH) | 2022-06-16 | — | — | US | disclosed |
| US-20200316081-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, CO., LTD. (CN) | 2020-10-08 | — | — | US | disclosed |
| US-20180098995-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | NOVARTIS AG (CH) | 2018-04-12 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1846406-A1 | MALEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ArQule, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006086484-A1 | MELEIMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098995-A1 | Combination Products with Tyrosine Kinase Inhibitors and their Use | EGFR, ERBB2, ERBB3 | MET 4/4885OPA1 4872/4885EIF5B 728/4885 |
| US-20200316081-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | EGFR, ERBB2, ERBB3 | MET 4/4885OPA1 4872/4885EIF5B 728/4885 |
| US-20220184090-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | EGFR, ERBB2, ERBB3 | MET 4/4885OPA1 4872/4885EIF5B 728/4885 |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | PDCD5, TP53, NUP205 | MET 2940/4885OPA1 27/4885EIF5B 341/4885 |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | MET 2895/4885OPA1 88/4885EIF5B 402/4885 |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | MCL1, BRCA1, IDO1 | MET 2849/4885OPA1 29/4885EIF5B 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.